Pain Management Company Showcases Innovative Product Results For IVR Rates

In a groundbreaking development that could significantly alter the landscape of post-surgical pain management, PainReform Ltd (NASDAQ: PRFX) has unveiled compelling results from recent studies showcasing the superior in-vitro release (IVR) rates of its innovative product, PRF-110, compared to the industry-leading pain management products. This revelation not only highlights the potential for improved patient care but also underscores the importance of non-opiate solutions in addressing post-operative pain. $PainReform(PRFX.US)$